Lots of debate in our household how to play TTWO. They report very soon. Only down a fraction for the month, maybe 2% not really getting the pull back we had hoped for. One side of the family says watch out this could be a kitchen sink earn report (everything bad thrown in) .. and the other side says we should get in in case they beat. How Would You Play it ? TTWO Take-Two Interactive Software, Inc. $140.99-1.19 (-0.84%)<----------- 2:56 PM 08/07/23 NASDAQ | $USD | Realtime
This is an all-timer. can't be a good sign can it? Biotech Firm Vistagen Surges 1,370% on Social Anxiety Spray Trial Success Angel Adegbesan Mon, August 7, 2023, 1:51 PM EDT (Bloomberg) -- A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., is having its best day ever, surging north of four digits after its experimental nasal spray for social anxiety disorder hit targets in a late-stage trial. Shares of the drug developer surged by a record 1,370% on Monday, sending the stock to its highest level in more than a year. The unexpected success pushed the stock’s market value to above $130 million, a level it had been trading below for the better part of a year amid a broad market selloff in risky assets and a prior trial setback. Vistagen said the study of fasedienol nasal spray met its main goal, showing improvements on patients’ reported distress in a public speaking challenge while a secondary goal was also met with no severe or serious adverse events reported. The stock had been setting record lows this year after a previous late-stage trial of the drug failed to reach its main goal using the same scale measuring patient distress, dubbed SUDS, last year. “Fasedienol demonstrated a rapid and very clinically meaningful reduction in SUDS score, indicating a single administration has the potential to reduce anxiety symptoms during an anxiety-provoking situation,” Michael Liebowitz, a founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute and a member of Vistagen’s advisory board, said in a statement. An additional late-stage study is planned. That will include multiple administrations of the spray over several weeks on what the company said will be “a patient-tailored, as-needed basis.” The stock had four analysts covering it with a buy rating as of last July, before the stock plunged. Now, the lone analyst tracked by Bloomberg that covers the stock rates it a hold. US-listed shares of Australian peer Bionomics Ltd. surged as much as 69% before paring gains to trade up around 3%. Bionomics is also developing a social anxiety drug.
This is not good... Overnight tell me this is an ink smudge... Scary. https://www.youtube.com/shorts/nmHzvQr3kYE
Just an ink smudge. Motion-capture with a 3D rendering over the player. Skynet is not yet fully aware.
Dateline NYC- Cathie Wood's ARK Investment bought 659.6K shares of Pacific Biosciences today 20:08 PACB
Quanterix sees FY23 revenue $110M-$116M, consensus $108.45M » 17:17 QTRX Quanterix reports Q2 EPS (16c), consensus (38c) » 17:16 QTRX
CTRA Coterra Energy raises FY23 production view to 630-655 Mboepd » 16:30 CTRA Coterra Energy sees Q3 production 625-655 MBoepd » Coterra Energy reports Q2 adjusted EPS 39c, consensus 34c » 16:29 CTRA